Chris Freitag

Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.

PIramed Ltd. develops drugs, diagnostics, and other therapeutic products. It develops treatment for cancers which include proliferation, invasion, angiogenesis, and metastasis. The company was co-founded by Michael Waterfield, Peter Parker, and Paul Workman in 2003 and is headquartered in Slough, UK.

FoldRx Pharmaceuticals, Inc. provides drug discovery and clinical development services. It develops and discovers products focusing on first-in-class, disease-modifying, small molecule therapeutics to treat diseases of protein misfolding. The company was founded by Jeffery W. Kelly and Susan L. Lindquist in 2003 and is headquartered in Cambridge, MA.

The Institute of Cancer Research: Royal Cancer Hospital operates as a cancer research institution. The company was founded in 1909 and is headquartered in London, the United Kingdom.

Spectrum Ltd., engages in manufacturing accessories for video games. The company is headquartered in Jessup, MD.

Cancer Research Ventures Ltd. engages in the business of research and experimental development on biotechnology. It provides medical products. The company is headquartered in London, the United Kingdom.

Cancer Research Technology Ltd. develops cancer therapeutics, vaccines, and diagnostics. The firm also provides project development, commercialization, drug discovery, clinical development, imaging, and funding services. The company was founded in 2002 and is headquartered in London, the United Kingdom.

Innovata Ltd. researches and develops pharmaceutical and medical products. It develops pulmonary products for the treatment of respiratory disorders and other serious diseases. The company was founded on July 20,1987 and is headquartered in Nottingham, the United Kingdom.

Lifearc provides research services. It specializes in intellectual property management, drug discovery, medical diagnostics and antibody engineering. The firm services include complete technology transfer service for scientists in MRC units and institutes, Awards to Inventors, Collaborative drug discovery and antibody engineering, Funding early stage research with commercial/translational potential and protecting new ideas. The company is headquartered in London, the United Kingdom.

The UK Innovation & Science Seed Fund LP, an evergreen fund, invests in seed-stage companies located in the United Kingdom. It targets companies operating in biotechnology, synthetic biology, engineering, agriculture, computer science, and environmental technology sectors. It provides equity financing for seed to early-stage transactions.

OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden.

Cizzle Biotechnology Ltd. develops therapeutic products for lung cancer. The firm promotes DNA replication and is involved in its organization and control. The company was founded by Dawn Coverley and Justin Ainscough in 2005 and is headquartered in York, the United Kingdom.

AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands.

Celltech Ltd. provides research and development on natural science and engineering. The company was founded in 1999 and is headquartered in Slough, GB.

Evgen Ltd. develops novel glucosinolate based products for the prevention and treatment of human disease. It engages in the clinical stage drug development that lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. Its activities also include carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer. The firm holds proprietary technology that enables sulforaphane to be synthesized and then subsequently stabilized for pharmaceutical application. The company was founded by Dr. Stephen Franklin on October 18, 2007 and is headquartered in Liverpool, the United Kingdom.

Part of UCB SA, Celltech Group Ltd. is an investment holding British company. The company is based in Slough, UK. Celltech Group was founded in 1987.

Oxford Ancestors Ltd. provides portal engine and content management system. It offers maternal and paternal ancestry, genealogy services and database zone products. The company was founded by Bryan Clifford Sykes in 2000 and is headquartered in Bicester, the United Kingdom.

Butterfly Conservation is a British charity that aims to save butterflies, moths, and their habitats. Butterfly Conservation has more than 40,000 members in the UK and 32 volunteer-run branches throughout the British Isles. The non-profit company is based in Wareham, UK. The organization operates 36 nature reserves and is leading or involved in 73 landscape-scale projects to conserve habitats. The organization employs over 80 people, including many highly qualified scientists, making it the world's largest research institute for butterflies and moths. Butterfly Conservation's new strategy sets out three key goals to drive forward their work, making a pledge for the impact they will make on threatened species, doubling their impact on landscape restoration, and involving people in transforming spaces for butterflies and moths. The British company was founded in 1968, and Julie Williams has been the CEO of the company since 2000.

MedDay Pharmaceuticals SAS operates as a biotechnology company developing new drugs for nervous system disorders. The firm operates for the treatment of neuro-metabolic diseases. The company was founded by Frédéric Sedel and Guillaume Brion in 2011 and is headquartered in Paris, France.

SoniVie Ltd. engages in the development of a system for the treatment of pulmonary hypertension. Its products include Therapeutic Intra-Vascular Ultrasound (TIVUS) system, an intravascular, catheter-based technology that can cause denervation of nerves surrounding blood vessels and other structures like the bronchus. The company was founded by Moshe Arkin in 2014 and is headquartered in Rosh Haayin, Israel.

ReViral Ltd. specializes in the areas of virology and antiviral therapies. It offers drugs to treat respiratory synctial virus infection. The company was founded by Neil Matthews and Stuart Cockerill in 2011 and is headquartered in Stevenage, the United Kingdom.

Imcheck Therapeutics SAS operates as a biopharmaceutical company which develops immunotherapeutic anti-cancer strategies for research. The company was founded by Olive Daniel in 2015 and is headquartered in Marseille, France.

Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom.

Grey Wolf Therapeutics Ltd. is a biotechnology company, which engages in the drug discovery in immuno-oncology. It targets endoplasmic reticulum aminopeptidases 1 and 2 in the antigen presentation pathway to drive modulation of the neoantigen repertoire on tumour cells. The company was founded by Thomas D. McCarthy and Peter Joyce and is headquartered in Oxford, the United Kingdom.

Flamingo Therapeutics BV is a Belgian company that specializes in developing RNA-targeted therapies for oncology. The company is based in Leuven, Belgium and was founded by Mike Garrett and Floor Stam. Flamingo is dedicated to delivering therapeutic benefit to patients living with cancer and believes that their programs and approach can successfully address large unmet medical needs where RNA-targeting can be effective. The company's clinical-stage pipeline focuses on targeting undruggable transcription factors and splice variants. The CEO is Stephane van Rooijen.